Trevi Therapeutics, a clinical stage biotech developing therapies for neurological disorders, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The New Haven , CT-based company was founded in 2011 and plans to list on the Nasdaq under the symbol TRVI. Trevi Therapeutics filed confidentially on November 19, 2018. SVB Leerink, Stifel and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
